Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SPHL vs RADX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SPHL Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–1 Matrix Metrics)

SPHL Overall Winner 6-Pillar Tally: SPHL 5 – 0 RADX (1 Tie) Matrix Metrics: SPHL 6 – 1 RADX

As of Nov 20, 2026, Springview Holdings Ltd Class A (SPHL) is the stronger overall head-to-head candidate over Radiopharm Theranostics Limited (RADX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SPHL carries a Unified Composite Score of 48.7/100 (HOLD) at $2.41 (N/M Forward P/E, -24.1% operating margin), whereas RADX carries 41.1/100 (SELL) at $0.63 (N/M Forward P/E, -411.6% operating margin).

  • Technical & Structure Timing Caution: SPHL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.2); meanwhile RADX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SPHL vs RADX
SPHL NASDAQ Head-to-Head Winner
Springview Holdings Ltd Class A Ordinary Shares
General Bldg Contractors - Residential Bldgs
$2.41
-0.82% 1D
Market Cap $5.5M
TTM Revenue $9.2M
Forward P/E N/M
Beta / 30D Vol -1.44β · 102% Vol
Unified Composite Score
48.7 / 100 HOLD
Tech 45.0 Fund 58.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 50.2 · SMA20: $2.37 · SMA50: $2.43
RADX NASDAQ
Radiopharm Theranostics Limited American Depositary Shares
Pharmaceutical Preparations
$0.63
-6.33% 1D
Market Cap $10.6M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 0.52β · 109% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.5%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.86 · SMA50: $1.15

6-Pillar Scorecard Institutional Category Breakdown (SPHL 5 – 0 RADX)

Columns: Metric · SPHL · RADX
1. Valuation Multiples SPHL
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.6x 0.8x
2. Growth & Scale SPHL
Revenue Growth (YoY) +38.4% -36.9%
Earnings Growth (YoY) -6.9% +0.0%
TTM Revenue (USD) $9.2M $13M
Market Cap $5.5M $10.6M
3. Profitability & Quality SPHL
Gross Margin 16.4% N/A
Operating Margin -24.1% -411.6%
Net Profit Margin -23.4% 0.0%
Return on Equity (ROE) -35.4% -174.7%
4. Balance Sheet & Cash Flow SPHL
Cash Generation (TTM) -$2.2M EBITDA -$50M EBITDA
Cash Flow Margin -24.1% EBITDA Mgn N/A
Net Cash / Leverage $0.42 Book/Sh · -35.4% ROE $1.48 Book/Sh · -174.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat SPHL
OpEx & R&D Intensity 40.5% of Rev ($3.7M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Residential Construction Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SPHL (6) vs RADX (1)
Institutional Metric SPHL RADX Criterion Row Edge
Market Capitalization
Scale
$5.5M $10.6M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+38.4% -36.9% Higher Growth SPHL
Operating Margin (TTM)
Profitability
-24.1% -411.6% Higher Margin SPHL
Net Profit Margin
Profitability
-23.4% 0.0% Higher Margin RADX
Return on Equity (ROE)
Capital Efficiency
-35.4% -174.7% Higher ROE SPHL
52-Week Range Position
Momentum
8% ($0–$25) 0% ($1–$16) Stronger Trend SPHL
Beta / 30D Volatility
Risk Regime
-1.44β · 102% Vol 0.52β · 109% Vol Lower Realized Risk SPHL
Unified Institutional Score
Composite Signal
48.7 / 100 (HOLD) 41.1 / 100 (SELL) Higher Composite SPHL
Trailing 12M Revenue (USD)
Operating Scale
$9.2M $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.6x EV/Rev N/M PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.2M EBITDA ($0.42 Book/Sh · -35.4% ROE) -$50M EBITDA ($1.48 Book/Sh · -174.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SPHL +10.88 pp
SPHL: -22.76% · RADX: -33.64%
3M Horizon SPHL +67.57 pp
SPHL: -6.59% · RADX: -74.16%
6M Horizon SPHL +80.55 pp
SPHL: -5.86% · RADX: -86.41%
1Y Horizon SPHL +580.84 pp
SPHL: +495.5% · RADX: -85.34%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SPHL vs RADX. Trailing 12-month operating profitability (SPHL -24.1% vs RADX -411.6%) and valuation multiples (SPHL N/M vs RADX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SPHL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$9.2M
Gross Margin16.4%
Op. Margin-24.1%
ROE / Fwd P/E-35.4% · N/M
RADX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross MarginN/A
Op. Margin-411.6%
ROE / Fwd P/E-174.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SPHL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SPHL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RADX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RADX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SPHL Moat Profile Cyclical / Execution-Driven Positioning
Residential Construction Operator
Competes within the Residential Construction value chain with $5.5M market capitalization and -24.1% operating margin.
OpEx & R&D Reinvestment 40.5% of Rev ($3.7M)
90D Engineering Disclosures 0 Published
RADX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $10.6M market capitalization and -411.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SPHL vs RADX Key Questions & Quantitative Answers

As of Nov 20, 2026, Springview Holdings Ltd Class A (SPHL) is the stronger overall head-to-head candidate over Radiopharm Theranostics Limited (RADX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SPHL carries a Unified Composite Score of 48.7/100 (HOLD) at $2.41 (N/M Forward P/E, -24.1% operating margin), whereas RADX carries 41.1/100 (SELL) at $0.63 (N/M Forward P/E, -411.6% operating margin). Technical & Structure Timing Caution: SPHL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.2); meanwhile RADX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SPHL leads the Growth & Scale pillar: SPHL posts +38.4% YoY revenue growth and -6.9% YoY earnings growth on $9.2M TTM revenue (16.4% gross margin, -24.1% operating margin), compared with RADX at -36.9% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (N/A gross margin, -411.6% operating margin). On trailing 12-month operating scale, SPHL generates $9.2M in USD-normalized revenue versus $13M for RADX. In operating R&D and SG&A reinvestment, SPHL deploys 40.5% of Rev ($3.7M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RADX.

SPHL screens cheaper on headline valuation multiples. SPHL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.6x EV/Revenue (-24.1% EBITDA margin), whereas RADX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SPHL (-35.4% ROE) versus RADX (-174.7% ROE) capital efficiency.

In options market volatility and institutional positioning, SPHL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-1.44β · 102% Vol realized risk). By comparison, RADX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.52β · 109% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.